Navigation Links
Takeda Announces New U.S. Leadership
Date:3/19/2008

Proposed appointments effective at conclusion of TAP transaction

DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.

MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.

Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.

Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP's vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.

"I have great confidence in Takeda's proposed new leadership for the United States, an important market for Takeda's global growth plans," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nancy Joseph-Ridge is a well-known and highly respected physician, researcher and strong leader with an unwavering commitment to scientific excellence. I would also like to take this opportunity to thank Mark Booth for his many contributions to Takeda and wish him well in his future endeavors."

MacKenzie first joined TAP as a sales representative in 1985 and served in various senior-level roles for TAP, including vice president of sales and director of marketing. He holds a B.S.N. from Wagner College, a B.A. in economics from City University of New York, and a M.B.A. from the University of Chicago.

Prior to joining TAP in 2002, Dr. Joseph-Ridge worked for Searle, which later became part of Pfizer, in drug safety and clinical development. She previously held clinical and academic roles in Chicago at Rush-Presbyterian-St. Luke's Medical Center and the University of Chicago Hospitals. She received her M.D. from the University of Illinois at Chicago.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. Through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Takeda submits new drug application for alogliptin (syr-322) in the US
2. Chemizon Announces Research Collaboration Expansion With Takeda
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
6. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
7. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
9. PRA International Announces New Office Opening in Mumbai
10. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
11. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... York (PRWEB) , ... December 05, 2016 , ... ... the ability of physical therapist assistants, under direct supervision of a licensed physical ... obtains physical therapy receives a consultation and treatment plan from a licensed physical ...
(Date:12/5/2016)... , ... December 05, 2016 , ... As renowned, board-certified ... the dangers and downsides of patients who do not do their research and undergo ... cosmetic dermatology is in the midst of a renaissance and every other month a ...
(Date:12/5/2016)... ... 2016 , ... Z-Medica, LLC, a leading developer and marketer ... College of Surgeons (ACS) to provide basic bleeding control instructor training to surgeons. ... is a pilot program that fulfills the intent of the White House’s “Stop ...
(Date:12/4/2016)... ... 03, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... New York City, with long-time partners The Paul Foundation, on November 10, 2016. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... wins "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty ... France. , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)...  The Addiction Treatment Advisory Group (ATAG), created ... Pharmacy (AMCP), has released detailed findings on how ... addiction crisis, including through improved access to naloxone ... newly released paper, "The Role of Managed Care ... issues around gaps and barriers to addiction treatment ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: